96 related articles for article (PubMed ID: 30124372)
41. Omitting cytogenetic assessment from routine treatment response monitoring in chronic myeloid leukemia is safe.
Geelen IGP; Thielen N; Janssen JJWM; Hoogendoorn M; Roosma TJA; Valk PJM; Visser O; Cornelissen JJ; Westerweel PE
Eur J Haematol; 2018 Apr; 100(4):367-371. PubMed ID: 29288559
[TBL] [Abstract][Full Text] [Related]
42. Hypomethylation-mediated H19 overexpression increases the risk of disease evolution through the association with BCR-ABL transcript in chronic myeloid leukemia.
Zhou JD; Lin J; Zhang TJ; Ma JC; Li XX; Wen XM; Guo H; Xu ZJ; Deng ZQ; Zhang W; Qian J
J Cell Physiol; 2018 Mar; 233(3):2444-2450. PubMed ID: 28776669
[TBL] [Abstract][Full Text] [Related]
43. Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.
Khalil SH; Abu-Amero KK; Al Mohareb F; Chaudhri NA
Genet Test Mol Biomarkers; 2010 Feb; 14(1):67-74. PubMed ID: 19943786
[TBL] [Abstract][Full Text] [Related]
44. A multi-state model approach for prediction in chronic myeloid leukaemia.
Lauseker M; Hasford J; Hoffmann VS; Müller MC; Hehlmann R; Pfirrmann M;
Ann Hematol; 2015 Jun; 94(6):919-27. PubMed ID: 25465231
[TBL] [Abstract][Full Text] [Related]
45. BAX/BCL-XL gene expression ratio inversely correlates with disease progression in chronic myeloid leukemia.
Gonzalez MS; De Brasi CD; Bianchini M; Gargallo P; Moiraghi B; Bengió R; Larripa IB
Blood Cells Mol Dis; 2010 Oct; 45(3):192-6. PubMed ID: 20728382
[TBL] [Abstract][Full Text] [Related]
46. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.
Nicolini FE; Basak GW; Kim DW; Olavarria E; Pinilla-Ibarz J; Apperley JF; Hughes T; Niederwieser D; Mauro MJ; Chuah C; Hochhaus A; Martinelli G; DerSarkissian M; Duh MS; McGarry LJ; Kantarjian HM; Cortes JE
Cancer; 2017 Aug; 123(15):2875-2880. PubMed ID: 28387926
[TBL] [Abstract][Full Text] [Related]
47. Trends in all-cause mortality among patients with chronic myeloid leukemia: a Surveillance, Epidemiology, and End Results database analysis.
Brunner AM; Campigotto F; Sadrzadeh H; Drapkin BJ; Chen YB; Neuberg DS; Fathi AT
Cancer; 2013 Jul; 119(14):2620-9. PubMed ID: 23625575
[TBL] [Abstract][Full Text] [Related]
48. Barriers to physician adherence to evidence-based monitoring guidelines in chronic myelogenous leukemia.
Goldberg SL; Akard LP; Dugan MJ; Faderl S; Pecora AL
J Oncol Pract; 2015 May; 11(3):e398-404. PubMed ID: 25758446
[TBL] [Abstract][Full Text] [Related]
49. [A clinical and laboratory study of chronic myeloid leukemia with atypical BCR-ABL fusion gene subtypes].
Gui X; Pan J; Qiu H; Cen J; Xue Y; Chen S; Shen H; Yao L; Zhang J; Wu Y; Chen Y
Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):210-4. PubMed ID: 24666486
[TBL] [Abstract][Full Text] [Related]
50. Mortality and Vascular Events Among Elderly Patients With Chronic Myeloid Leukemia: A Retrospective Analysis of Linked SEER-Medicare Data.
Lang K; McGarry LJ; Huang H; Dorer D; Kaufman E; Knopf K
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):275-285.e1. PubMed ID: 27013180
[TBL] [Abstract][Full Text] [Related]
51. Impact of lung function on exacerbations, health care utilization, and costs among patients with COPD.
Ke X; Marvel J; Yu TC; Wertz D; Geremakis C; Wang L; Stephenson JJ; Mannino DM
Int J Chron Obstruct Pulmon Dis; 2016; 11():1689-703. PubMed ID: 27555759
[TBL] [Abstract][Full Text] [Related]
52. Molecular monitoring of Tunisian patients with chronic myeloid leukemia.
Menif S; Ben Youssef Y; Bellaaj H; Ben Lakhal R; Laatiri A
Tunis Med; 2017 Dec; 95(12):229-231. PubMed ID: 29878287
[TBL] [Abstract][Full Text] [Related]
53. [Ten years of molecular monitoring of chronic myeloid leukemia by quantitative RT-PCR].
Moravcová J; Brdicka R
Cas Lek Cesk; 2005; 144(1):32-7. PubMed ID: 15789779
[TBL] [Abstract][Full Text] [Related]
54. The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia.
Efficace F; Rosti G; Breccia M; Cottone F; Giesinger JM; Stagno F; Iurlo A; Russo Rossi A; Luciano L; Martino B; Galimberti S; Turri D; Bergamaschi M; Tiribelli M; Fava C; Angelucci E; Mandelli F; Baccarani M
Ann Hematol; 2016 Jan; 95(2):211-9. PubMed ID: 26546359
[TBL] [Abstract][Full Text] [Related]
55. Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase.
Guérin A; Chen L; Dea K; Wu EQ; Goldberg SL
Curr Med Res Opin; 2014 Jul; 30(7):1345-52. PubMed ID: 24640967
[TBL] [Abstract][Full Text] [Related]
56. Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.
Fava C; Rege-Cambrin G; Dogliotti I; Gottardi E; Berchialla P; Di Gioacchino B; Crasto F; Lorenzatti R; Volpengo A; Daraio F; Fantino C; Saglio G
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S96-S100. PubMed ID: 27131622
[TBL] [Abstract][Full Text] [Related]
57. Differential gene expression changes and their implication on the disease progression in patients with Chronic Myeloid Leukemia.
Chandran RK; Geetha N; Sakthivel KM; Kumar RS; Krishna KMNJ; Sreedharan H
Blood Cells Mol Dis; 2019 Jul; 77():51-60. PubMed ID: 30959263
[TBL] [Abstract][Full Text] [Related]
58. [Monitoring bcr-abl mRNA levels by real-time quantitative RT-PCR in chronic myeloid leukemia patients after hematopoietic stem cell transplantation].
Qin YZ; Li JL; Zhu HH; Ruan GR; Li LD; Zhang Y; Xu LP; Liu DH; Liu YR; Huang XJ; Chen SS; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2006 Aug; 27(8):511-4. PubMed ID: 17172121
[TBL] [Abstract][Full Text] [Related]
59. Myeloid Sarcoma as the First Sign of Progression of Chronic Myeloid Leukemia in Medullary Chronic Phase: Experience from a Tertiary Cancer Centre in Southern India.
Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, India
Gulf J Oncolog; 2017 Jan; 1(23):21-25. PubMed ID: 28271998
[TBL] [Abstract][Full Text] [Related]
60. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression.
Lee DS; Lee YS; Yun YS; Kim YR; Jeong SS; Lee YK; She CJ; Yoon SS; Shin HR; Kim Y; Cho HI
Genes Chromosomes Cancer; 2003 Jul; 37(3):291-9. PubMed ID: 12759927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]